Suven Life Sciences Limited
Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.
What Suven files
- Others58
- Updates17
- Board Meeting14
- Important5
- Insider Trade3
- QIP/Rights/Pref.3
Suven Life Sciences completed patient enrollment for its global Phase-3 Masupirdine study (SUVN-502) for Alzheimer’s Dementia agitation. 424 patients were randomized. Topline results are anticipated by May 2027, signaling progress in its CNS pipeline.
Suven Life Sciences has made its FY2026 Annual Report available online. Shareholders are encouraged to update their PAN, KYC details, and nomination records for smooth electronic payments. A dedicated senior citizen investor cell is also available. #SuvenLife #ShareholderUpdate
Suven Life Sciences, an R&D specialist, reported FY26 turnover of ₹7.11 Cr and net worth of ₹1,503.37 Cr. Employee well-being spending increased to 16.47% of revenue. Environmental performance indicates higher energy/GHG/water intensity per rupee of turnover, though waste intensity decreased. 90% inputs are sustainably sourced. No regulatory fines or complaints...
Suven Life Sciences will present five scientific posters at a global Alzheimer's conference, detailing updates on its Phase-3 Masupirdine study for Alzheimer's Agitation and Phase-2 Usmarapride program for cognitive disorders, alongside other neuroscience pipeline developments.
Suven Life Sciences allotted 1.86 Cr shares via warrant conversion, raising ₹248.84 Cr, significantly boosting its paid-up capital. The company is also incorporating a Singapore subsidiary for biopharmaceutical clinical development, involving an investment of up to $100M.